After Medivation Sale, ex-CEO David Hung Lands Top Spot At Axovant

Axovant Sciences, with a high-profile Alzheimer’s treatment in Phase 3 studies, has brought on David Hung as CEO. Hung was founder, president, and CEO of San Francisco-based Medivation, which Pfizer (NYSE: [[ticker:PFE]]) bought for $14 billion last year, in large part to gain control of the prostate cancer drug enzalutamide (Xtandi).

Medivation’s Marion McCourt will also join Axovant (NYSE: [[ticker:AXON]]) as president and COO, and two former Medivation directors are joining the Axovant board. Axovant founding CEO Vivek Ramaswamy will continue to run Axovant’s parent company Roivant Sciences. Axovant’s Phase 3 MINDSET study is expected to release results in September, the company said.

Author: Alex Lash

I've spent nearly all my working life as a journalist. I covered the rise and fall of the dot-com era in the second half of the 1990s, then switched to life sciences in the new millennium. I've written about the strategy, financing and scientific breakthroughs of biotech for The Deal, Elsevier's Start-Up, In Vivo and The Pink Sheet, and Xconomy. View all posts by Alex Lash